Reves J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021;2:100070.

Article  PubMed  PubMed Central  Google Scholar 

Winthrop KL, Weinblatt ME, Bathon J, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88–93.

Article  PubMed  Google Scholar 

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

Article  CAS  PubMed  Google Scholar 

Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626–33.

PubMed  Google Scholar 

World Health Organization. Global report on psoriasis. 2016. http://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf. Accessed 13 Dec 2022.

Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.

Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 (e42; quiz e30).

Article  PubMed  Google Scholar 

Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lemann score. Inflamm Bowel Dis. 2011;17(6):1415–22.

Article  PubMed  Google Scholar 

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70.

Article  PubMed  Google Scholar 

Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn’s disease. Am J Gastroenterol. 2002;97(8):1994–9.

Article  PubMed  Google Scholar 

Zlatkovic-Svenda MI, Saraux A, Tuncer T, et al. FRI0558 rheumatoid arthritis prevalence in Europe, a Eular-endorsed survey. Ann Rheum Dis. 2016;75(Suppl 2):643.

Google Scholar 

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.

Article  CAS  PubMed  Google Scholar 

Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545–68.

Article  Google Scholar 

Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54(5):792–7.

Article  PubMed  Google Scholar 

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70.

Article  PubMed  Google Scholar 

Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436–48.

Article  PubMed  Google Scholar 

Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin North Am. 2012;38(3):441–76.

Article  PubMed  PubMed Central  Google Scholar 

Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650–7.

Article  PubMed  Google Scholar 

Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology. 2020;161(2):94–102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556–62.

Article  PubMed  Google Scholar 

Lopez-Medina C, Ramiro S, van der Heijde D, Sieper J, Dougados M, Molto A. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2):e001108.

Article  PubMed  PubMed Central  Google Scholar 

Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53(5):585–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl 1):i37–46.

Article  PubMed  Google Scholar 

Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021;372:m4447.

Article  PubMed  Google Scholar 

Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.

Article  PubMed  Google Scholar 

Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742–53.

Article  PubMed  Google Scholar 

Dignass A, Dotan I, Lindsay J. Evolving treatment options for patients with ulcerative colitis (UC). 2022. https://www.ecco-ibd.eu/publications/ecco-news/item/2022-1-evolving-treatment-options-for-patients-with-ulcerative-colitis-uc.html. Accessed 30 May 2023.

National Health Service England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf. Accessed 13 Dec 2022.

National Institute for Health and Care Excellence. Systemic biological therapy for psoriasis. 2021. https://pathways.nice.org.uk/pathways/psoriasis/systemic-biological-therapy-for-psoriasis.pdf. Accessed 10 Feb 2022.

Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296.

Antolin-Fontes B, Borsi A, Nissinen R, et al. P091 Switching to TNFi versus non-TNFi biologics in Crohn’s disease patients: real-world outcomes from a German claims data analysis. J Crohns Colitis. 2021;15(Suppl_1):S189–91.

Article  Google Scholar 

Bogas P, Plasencia C, Navarro-Compan V, et al. FRI0079 Long-term clinical efficacy of cycling vs switching to a non-TNF inhibitor in RA patients who failed to a first TNF inhibitor. Ann Rheum Dis. 2019;78(Suppl 2):701.

Google Scholar 

Egeberg A, Danø A, Pedersen M, Sohrt A, Borg E, Notario J. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. J Med Econ. 2021;24(1):1134–42.

Article  PubMed  Google Scholar 

Klijn SL, van den Reek JMPA, van de Wetering G, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018;178(5):1181–9.

Article  CAS  PubMed  Google Scholar 

Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:2682.

Article  Google Scholar 

Chang W, Cheng J, Allaire JJ, et al. Shiny. Web Application Framework for R. 2021. https://CRAN.R-project.org/package=shiny. Accessed 23 Oct 2022.

Chen C, Zhang X, Xiao L, Zhang X, Ma X. Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis. Medicine (Baltimore). 2016;95(11):e3060.

Article  PubMed  Google Scholar 

Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76(3):571–92.

Article  CAS  PubMed  Google Scholar 

Committee for Medicinal Products for Human Use (CHMP). Assessment report - Cimzia. Procedure No. EMEA/H/C/001037/II/0065. 26 April 2018. https://www.ema.europa.eu/en/documents/variation-report/cimzia-h-c-1037-ii-0065-epar-assessment-report-variation_en.pdf. Accessed 26 Nov 2019.

Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60.

Article  CAS  PubMed  Google Scholar 

Varu A, Wilson FR, Dyrda P, Hazel M, Hutton B, Cameron C. Treatment sequence network meta-analysis in Crohn’s disease: a methodological case study. Curr Med Res Opin. 2019;35(5):733–56.

Article  CAS  PubMed  Google Scholar 

National Institute for Health and Care Excellence. Golimumab for treating non-radiographic axial spondyloarthritis. 2018. https://www.nice.org.uk/guidance/ta497. Accessed 26 Nov 2019.

Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.

Article  CAS  PubMed  Google Scholar 

Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31.

Article  CAS  PubMed  Google Scholar 

Cameron C, Druchok C, Hutton B, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis during induction phase: a systematic review and network meta-analysis. J Psoriasis Psoriatic Arthritis. 2019;4(2):81–92.

Article  Google Scholar 

Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–69.

Article  PubMed  PubMed Central  Google Scholar